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Abstract
Background: DAL-1 (Differentially Expressed in Adenocarcinoma of the Lung)/4.1B is a member
of the protein 4.1 superfamily that has been shown to suppress growth in lung, breast and brain
tumor cells. In the case of the caspase-3 deficient MCF-7 breast cancer cells, this growth
suppression has been shown to be partially mediated by the induction of apoptosis. However the
exact mechanism of action of DAL-1/4.1B is unknown. Recently, protein arginine N-
methyltransferase 3 (PRMT3) was identified as a DAL-1/4.1B interacting protein. Protein arginine
methyltransferases (PRMTs) posttranslationally methylate the arginine residues of proteins, a
modification which has been implicated in the regulation of multiple cellular processes including
nuclear-cytoplasmic transport, signal transduction, and transcription.
Results: To investigate the role of protein methylation in cell death induced by DAL-1/4.1B, DAL-
1/4.1B-inducible MCF-7 cells were examined for apoptosis and caspase activation in the absence
and presence of the protein methylation inhibitor adenosine dialdehyde (AdOX). Flow cytometry
analysis revealed that apoptosis was primarily associated with the activation of caspase 8, and
inhibition of this activation blocked the ability of DAL-1/4.1B to induce cell death.
Conclusion:  These results suggest that protein methylation cooperates with DAL-1/4.1B-
associated caspase 8-specific activation to induce apoptosis in breast cancer cells.
Background
Differentially expressed in adenocarcinoma of the lung
(DAL-1)/4.1B is a tumor suppressor gene belonging to the
Protein 4.1 superfamily [1]. Like other members of this
family, DAL-1/4.1B localizes to the cell membrane and
contains an N-terminal 4.1/ezrin/radixin/moesin (FERM)
domain [2] and spectrin/actin binding sequences. When
introduced into DAL-1/4.1B-null lung, breast and menin-
gioma cancer cell lines, this Protein 4.1 family member
significantly suppresses growth, in part through the induc-
tion of apoptosis [1,3,4]. However, the pathways via
which DAL-1/4.1B exerts its growth suppressing proper-
ties are still poorly understood.
The FERM domain of the founding family member Pro-
tein 4.1R has been found to associate with several mem-
brane proteins, including erythrocyte band 3, calmodulin,
glycophorin C, p55 and spliceosome-associated pICln [5-
7]. Similarly, merlin/NF2 associates with several trans-
membrane proteins including CD44 via residues in the N-
terminal FERM domain [8,9]. The interaction of merlin/
NF2 with CD44 has been shown to be critical for its
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growth suppression [8,10]. Hypothesizing that the unique
binding partners for DAL-1/4.1B may help elucidate its
mechanism of action as a negative growth regulator, yeast
two-hybrid analysis was performed using the 336 residues
of DAL-1/4.1B FERM domain and a fetal lung cDNA
library. Several strongly associating proteins, including
14-3-3 protein isoforms β,  γ and η [11] and protein
arginine N-methyltransferase 3 (PRMT3) [12] were iden-
tified. PRMT3 and its family members post-translationally
form asymmetric ω-NG, NG- (Type I enzymes; PRMT1, 2,
3, 4, and 6) or symmetric w-NG, N'G- (Type II enzymes;
PRMT5) dimethylarginine residues on proteins. This pro-
tein modification has been shown to regulate transduc-
tion of signals to the nucleus, transcription regulation
through nuclear receptors, and RNA transport between
the nucleus and cytoplasm [13-19]
Recently we have reported that DAL-1/4.1B regulates the
methylation of substrates by PRMT3 [12] and PRMT5 [20]
both in vitro and in cultured cells. Based on these findings,
post-translational protein methylation may be one mech-
anism by which DAL-1/4.1B suppresses growth and
induces apoptosis in MCF-7 cells. To address this, DAL-1/
4.1B-induced apoptosis and caspase activation were ana-
lyzed in both control and hypomethylated MCF-7 cells.
These studies show that DAL-1/4.1B induces apoptosis via
caspase 8 activation and that hypomethylation of cellular
proteins increases apoptosis as well as DAL-1/4.1B pro-
tein levels. These findings suggest that the interaction of
the tumor suppressor DAL-1/4.1B and protein methyla-
tion pathway components is biologically important in
controlling tumorigenesis.
Results
DAL-1/4.1B induces apoptosis in MCF-7 cells via a caspase 
8 dependent pathway
Previous work from this laboratory identified DAL-1/4.1B
protein as a growth suppressor and apoptosis-inducing
protein in MCF-7 cells, which themselves do not express
endogenous DAL-1/4.1B [3]. In agreement with this find-
ing, DAL-1/4.1B-inducible MCF-7 Cl27 cells underwent
apoptosis when treated with 2 µM Muristerone A for 48
hours to induce DAL-1/4.1B expression. The presence of
DAL-1/4.1B protein was confirmed by both Western blot
analysis and flow cytometry (FACS)(Figure 1A and 1B).
TUNEL analysis revealed that 48 hours of DAL-1/4.1B
protein expression induced apoptosis. Not all cells in the
MCF-7 Cl27 clone express robust levels of DAL-1/4.1B
protein, even after repeated subcloning. Therefore we also
analyzed the sub-population of cells that showed high
levels of DAL-1/4.1B protein. In that analysis, apoptosis
levels reached approximately 80% (Figure 1C).
To better understand the apoptotic mechanisms invoked
in MCF-7 cells upon expression of DAL-1/4.1B, global as
well as specific caspase activation was examined. FAM-
VAD-FMK, a potent inhibitor of caspase activity that irre-
versibly binds to the reactive cysteine residue of the large
subunit of caspases 1–9, was incubated with MCF-7 Cl27
cells with or without induction of DAL-1/4.1B protein
expression to assess global caspase activation. These
probes utilize carboxyfluorescein(FAM)-labeled peptide
fluoromethyl ketone (FMK) caspase inhibitors (FAM-pep-
tide-FMK) and allow the fluorescent detection of active
caspases in living cell systems. As shown in Figure 2A, the
presence of DAL-1/4.1B protein increased global caspase
activation levels by 2.5-fold suggesting that DAL-1/4.1B-
induced apoptosis proceeds through a caspase-dependent
pathway.
Three main effector caspases, caspases 3, 6 and 7, are
thought to be directly involved in the execution of cas-
Induction of DAL-1/4.1B-expression in MCF7 Cl27 cells  induces apoptosis Figure 1
Induction of DAL-1/4.1B-expression in MCF7 Cl27 cells 
induces apoptosis. A. Western blot analysis showing the 
induction of DAL-1/4.1B protein in MCF-7 Cl27 cells follow-
ing treatment with 2 µM muristerone for 48 hours. B. Flow 
cytometric analysis confirming the induction of DAL-1/4.1B 
in cells treated with 2 µM Muristerone (clear peak) as com-
pared to untreated cells (grey peak). C. The level of apopto-
sis in the total cell population and in cells specifically 
expressing measurable levels of DAL-1/4.1B protein was 
determined by TUNEL assay and detected by FACS.Molecular Cancer 2006, 5:4 http://www.molecular-cancer.com/content/5/1/4
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pase-dependent apoptosis. Importantly, MCF-7, as well as
the derivative DAL-1/4.1B-inducible Cl27 cell line, are
Caspase 3-deficient [21]. Therefore, we tested the ability
of DAL-1/4.1B expression to activate specific caspases
other than caspase 3 and including caspases 1, 2, 6, 7, 8,
9, 10 and 13. Using caspase specific binding peptides,
only caspase 8 (p = 0.007) showed highly statistically sig-
nificant activation when compared with cells without
DAL-1/4.B (Figure 2B). Caspase 7 is thought to function
downstream of caspase 3 but in some cases, caspase-7 can
be activated in caspase-3 deficient cells, inducing cleavage
of PARP [22-25]. Western blot analysis shows no PARP
cleavage in response to induced DAL-1/4.1B expression
(Figure 2C), suggesting that Caspase-7 is not specifically
activated during DAL-1/4.1B-associated apoptosis in
these cells.
If caspase 8 is directly involved in DAL-1/4.1B-associated
apoptosis, then inhibition of caspase 8 activation should
prevent cells from dying in response to the presence of the
DAL-1/4.1B protein. In support of this hypothesis, incu-
bation of DAL-1/4.1B-expressing MCF-7 Cl27 cells with
the caspase 8-specific inhibitor z-IETD-FMK resulted in
blockage of apoptosis in a dose-dependent manner (Fig-
ure 2D). Incubation of cells with this inhibitor in the
absence of DAL-1/4.1B protein had no effect. Several pub-
lications have previously documented the ability of cas-
pase 8 activation to mediate the cleavage of downstream
substrates and induce apoptosis in the absence of activa-
tion of downstream effecter caspases 3, 6 and 7 [26].
Therefore, DAL-1/4.1B-induced apoptosis in MCF-7 Cl27
cells may involve a caspase 8-dependent pathway which
functions independent of the major effector caspase path-
ways.
While our data suggests that caspase 8 is primarily
involved in DAL-1/4.1B mediated apoptosis in MCF-7
cells, the possibility that caspase 3 would also be acti-
vated, if present, was tested. To this end, caspase 3-
expressing MCF-7 Cl27 cells were generated [21,27] and
caspase 3 expression confirmed in several isolated clones
(Figure 3A). Subsequent induction of DAL-1/4.1B expres-
sion in these clones (as represented by Cl27.11 in Figure
3B) did not enhance the previously measured level of
apoptosis in these cells (8%) [3] suggesting that DAL-1/
4.1B-associated apoptosis does not require this major
effector caspase.
Protein methylation and DAL-1/4.1B cooperate to induce 
apoptosis in MCF-7 cells
Given that DAL-1/4.1B has recently been shown to mod-
ulate the ability of the arginine methyltransferases PRMT3
[12] and PRMT5 [20] to methylate cellular substrates, we
asked whether posttranslational protein methylation
might also play a role in DAL-1/4.1B-associated apopto-
Caspase activation in DAL-1/4.1B-induced MCF-7 cells Figure 2
Caspase activation in DAL-1/4.1B-induced MCF-7 cells. A. 
Global caspase activation in cells treated with 2 µM Murister-
one for 48 hours or 1 µM staurosporine (STS) for 4 hours. 
B. FACS analysis of the activation of Caspases 1, 2, 6, 8, 9, 10 
and 13 in cells with and without the induction of DAL-1/4.1B 
expression by treatment with 2 µM Muristerone for 48 
hours. Clear bars represent untreated cells; grey bars repre-
sent DAL-1/4.1B-expressing cells. Caspase 1, p = 0.232; Cas-
pase 2, p = 0.64; Caspase 6, p = 0.625; Caspase 8, p = 0.007; 
Caspase 9, p = 0.16; Caspase 10, p = 0.10; Caspase 13, p = 
0.039. C. Caspase 7 activation was investigated by Western 
blot analysis of PARP cleavage on proten lysates from unin-
duced and DAL-1/4.1B-induced MCF-7 Cl27 cells. D. Inhibi-
tion of caspase 8 activation blocks DAL-1/4.1B-associated 
apoptosis in a dose-dependent manner. This suggests that 
caspase 8 activation is critical for the induction of cell death 
by this tumor suppressor protein.Molecular Cancer 2006, 5:4 http://www.molecular-cancer.com/content/5/1/4
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sis. To address this, DAL-1/4.1B-inducible MCF-7 Cl27
cells were grown for 48 hours in the presence of 30 µM
periodate-oxidized adenosine (AdOX). AdOX, an inhibi-
tor of S-adenosylhomocysteine (AdoHcy) hydrolase,
which elevates the levels of AdoHcy in cultured mamma-
lian cells. Since AdoHcy is a product inhibitor of methyl-
transferases using AdoMet as the methyl donor, AdOX can
reduce the activity of protein methyltransferases in cul-
tured cells and consequently allow the accumulation of
hypomethylated protein substrates. Hypomethylated
MCF-7 Cl27 cell lysates were collected and the methyla-
tion status of endogenous PRMT substrates analyzed by
Western blot using the anti-asymmetric dimethylarginine
antibody ASYM 24. Figure 4A shows that asymmetrically
dimethylated proteins in MCF-7 Cl27 cells were signifi-
cantly, although not completely, inhibited by treatment
with 30 µM AdOX. Higher AdOX concentrations resulted
in significant cellular toxicity (data not shown).
To determine the effect of protein hypomethylation on
DAL-1/4.1B-induced apoptosis, MCF-7 Cl27 cells were
induced to express DAL-1/4.1B protein in the presence of
30 µM AdOX and analyzed for apoptosis levels as well as
global caspase activation. While treatment with AdOX
had no effect on apoptosis, protein hypomethylation sig-
nificantly increases the induction of cell death by DAL-1/
4.1B (Figure 4B). This suggests that the modulation of
protein methylation may be an important mechanism of
DAL-1/4.1B-induced apoptosis.
Discussion
Apoptosis is traditionally characterized by a series of mor-
phological features such as chromatin condensation,
nuclear fragmentation, and the appearance of membrane-
enclosed apoptotic bodies. Many proteins, including the
caspase family of aspartate-specific cysteine proteases,
have been reported to play a pivotal role in the apoptotic
process [28-31]. However, caspase-independent pathways
are emerging [32]. It has been shown previously that
expression of the tumor suppressor DAL-1/4.1B can
induce apoptosis in MCF-7 breast cancer cells [3] but the
mechanism(s) involved have not yet been identified.
More recently, it was reported that DAL-1/4.1B interacts
with members of the protein arginine N-methyltrans-
ferase family (PRMTs) and modulates the posttransla-
tional methylation of cellular substrates. In addition, it
was determined that DAL-1/4.1B was not itself a substrate
for this post-translational arginine methylation [12]. In
this report, we examined the caspase-dependence of DAL-
1/4.1B-induced apoptosis and the effect of inhibiting pro-
tein methylation on this cell death in MCF-7 cells, to
determine if post-translational protein methylation is one
potential mechanism through which DAL-1/4.1B exerts
its growth suppressive properties.
Previously [3] and in this report, induction of DAL-1/4.1B
expression was shown to induce apoptosis in MCF-7 cells.
Examination of a series of caspases revealed that these
apoptotic events occurred without activation of the three
major effector caspases (caspases 3, 6 and 7) but did result
in a significant increase in caspase 8 (p = 0.007) activa-
tion. The addition of the caspase 8-specific inhibitor z-
VAD-FMK blocked the ability of DAL-1/4.1B to stimulate
apoptosis in these cells in a dose dependent manner. Fur-
thermore, restoration of caspase 3 expression did not
increase the measured levels of apoptosis following DAL-
1/4.1B expression demonstrating that this caspase is not
activated even when present. However, restoration of cas-
pase-3 expression was recently shown to sensitize MCF-7
cells to radiation-induced apoptosis exhibiting the hall-
marks of a traditional effector caspase activation pathway
[33]. Our results suggest that cell death induced by DAL-
1/4.1B expression does not proceed via a classic caspase
activation cascade, but rather relies solely on one caspase,
caspase 8.
This lack of effector caspase activation in DAL-1/4.1B-
induced apoptosis is intriguing. Activation of these cas-
pases is one of the major characteristics in the pro-
grammed cell death process [34]. However, some cells
survive caspase activation, and accumulating evidence
suggests that many caspase-activating apoptotic stimuli,
including oncogenes, p53, DNA-damaging drugs, proap-
optotic Bcl2- family members, cytotoxic lymphocytes, and
in some cases even death receptors, do not necessarily
require activation of the known effector caspases for pro-
grammed cell death to occur [35].
Activation of upstream caspases such as caspase 8 has
been reported in both mitochondrial-independent and -
dependent pathways [36-39]. Activated caspase 8 has
been reported to trigger cell death by activating either
effector caspases 3, 6 or 7, or DNA damage enzymes such
as endonuclease G and AIF. Caspase-induced release of
EndoG from mitochondria results in cell apoptosis. Li and
colleagues [26] reported apoptosis with activated caspase
8 without activation of effector caspases. A parallel condi-
tion – activated caspase 8 without activation of caspases 3,
6, or 7 – occurs when DAL-1/4.1B protein is expressed in
MCF-7 cells although preliminary studies did not show
the release of EndoG into the cytoplasm (data not
shown).
Caspase-8 can also cross talk with calpain-dependent
apoptotic pathways. Benjamin and colleagues found that
both caspase-8 inhibitor z-IETD and calpain inhibitors
can protect mature mouse oligodendrocytes from cell
death initiated by staurosporine, thapsigargin and kainite
[40]. Their results suggest that crosstalk occurs between
the caspase and calpain pathways, upstream of an irrevers-Molecular Cancer 2006, 5:4 http://www.molecular-cancer.com/content/5/1/4
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ible cascade leading to cell death in mature oligodendro-
cytes. The cross-talk between caspase 8 and calpain has
also been identified in vascular smooth muscle cells dur-
ing Fas-associated apoptosis [41]. DAL-1/4.1B could also
induce apoptosis through membrane protein proteases
such as calpains. A related 4.1 family tumor suppressor,
NF2, has been shown to interact with calpains in neurofi-
bromatosis-related tumors [42]. In the case of the NF2
tumors, some patients lacking functional mutations in the
NF2 gene have concomitant overactive calpain protease
activity, which effectively degrades the existing NF2 pro-
tein, creating a "loss of tumor suppressor protein"-equiv-
alent environment. The potential relationship between
DAL-1/4.1B and calpains and their relationship to apop-
tosis is important to examine further.
Although protein methylation has been shown to be
involved in such cellular processes as signal transduction
and transcription [43] no evidence connecting protein
methylation and apoptosis has been reported previously.
AdOX, an inhibitor of s-adenosylhomocysteine (AdoHcy)
hydrolase, can inhibit methylation by elevating the cellu-
lar level of AdoHcy to inhibit the activity of methyltrans-
ferases [44]. As AdoHcy is a general inhibitor of the once
carbon metabolism pathway, its elevation could also
inhibit DNA as well as RNA methylation events.
Hypomethylation of cellular methyl-accepting protein
substrates by AdOX has been demonstrated previously
[44-49] and confirmed in this study (Figure 4A). Rat phe-
ochromocytoma (PC12) cells treated with 30 µM AdOX
for 72 hours were found to undergo a 50% decrease in
growth rate [44]. In the present analysis, apoptosis levels
in MCF-7 cells were not affected by the hypomethylating
treatment of cells with 30 µM AdOX for 48 hours. How-
ever, AdOX treatment appeared to enhance apoptosis
when the DAL-1/4.1B protein was expressed in MCF-7
cells. RNA methylation has also been shown to be altered
by AdOX treatment [50] and such methylation could reg-
ulate protein synthesis [51-53]. DAL-1/4.1B has previ-
ously been shown not to be a substrate for PRMT3- (Singh
et al., 2004) or PRMT5-mediated (Jiang et al., 2005)
arginine methylation but no information is currently
available as to the presence of methylated DAL-1/4.1B
mRNA species.
Further investigation into the relationship between DAL-
1/4.1B, protein methylation and apoptosis is required to
determine the exact mechanism(s) by which tumor cell
growth and apoptosis are regulated by these proteins. The
determination that caspase 8 activation occurs in the
absence of effector caspase activation suggests a poten-
tially novel pathway combining aspects of both tradi-
tional caspase-dependent cell death and the emerging
effector caspase-independent pathways of apoptosis. Fur-
thermore, the interaction between a tumor suppressor
(DAL-1/4.1B) and a post-translational methylation
enzyme (PRMTs) is likely to be an important modulator
of this pathway and so be of significant biological impor-
tance in controlling tumorigenesis in breast cancer cells.
Conclusion
In this report, caspase 8-specific activation by the tumor
suppressor DAL-1/4.1B is identified in the absence of acti-
vation of effector caspases 3, 6, or 7, suggesting a poten-
tially novel apoptotic pathway combining aspects of both
traditional caspase-dependent cell death and the emerg-
ing effector caspase-independent pathways of apoptosis.
Second it is shown that there is cooperation between DAL-
1/4.1B and post-translational protein methylation in the
induction of apoptosis in MCF-7 cells. This suggests that
the previously published interaction between the tumor
Restoration of caspase 3 expression does not enhance DAL- 1/4.1B-induced apoptosis Figure 3
Restoration of caspase 3 expression does not enhance DAL-
1/4.1B-induced apoptosis. A. Western blot analysis of Cas-
pase-3-deficient MCF-7 and DAL-1/4.1B-inducible Cl27 cells. 
CL 27.2, CL 27.7 and CL 27.11 are Caspase-3-expressing 
MCF-7 DAL-1/4.1B-inducible clones. B. Apoptosis levels 
measured up to 4 days after DAL-1/4.1B -expression in MCF-
7 CL 27.11 cells. TUNEL positive cells were counted in a 
microscopic field of 200 cells as previously reported [3] The 
expression of Caspase-3 does not significantly alter the apop-
tosis levels over that previously shown in Figure 2A for the 
caspase-3-deficient MCF-7 Cl27 cells.Molecular Cancer 2006, 5:4 http://www.molecular-cancer.com/content/5/1/4
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suppressor DAL-1/4.1B and the post-translational methyl-
ation enzymes (PRMTs) is likely to be an important mod-
ulator of this apoptotic pathway and so be of significant
biological importance in controlling tumorigenesis in
breast cancer cells.
Methods
Cell culture
MCF-7 cells were obtained from the American Type Cul-
ture Collection (Manassas, VA) and maintained in MEM
with 10% Fetal Calf Serum (FCS), sodium pyruvate, non-
essential amino acids and insulin. The MCF-7 Cl27 cell
line is a DAL/4.1B-inducible cell line generated from the
parental MCF-7 cell line using the Ecdysone Muristerone-
inducible Expression Kit (InVitrogen) [3]. DAL-1/4.1B
expression is induced by the addition of 2 µM Murister-
one to the culture medium for 48 hours. Hypomethyla-
tion of cells was carried out by addition of 30 µM AdOX
(adenosine, periodate oxidized; Sigma) to the culture
medium for 48 hours. A positive control for apoptotic
cells was obtained by incubating cells in 1 µM Stau-
rosporine (STS, Sigma) for 4 hours.
Western blot
Cell lysates were prepared in RIPA buffer (50 mM Tris,
150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate,
1% NP40) with protease inhibitors (Roche). Electro-
phoresis was performed on 10% SDS-PAGE gel (BioRad)
and transferred onto PVDF plus membrane (MSI Inc)
using the BioRad mini Protean II transfer system as previ-
ously described [1]. PARP antibody (Cell Signaling) was
used at a 1:1000 dilution for the assessment of caspase 7
activation. Inhibition of protein methylation by AdOX
treatment was determined using the anti-asymmetric
arginine methylation antibody ASYM24 (Upstate Bio-
tech) at a 1:1000 dilution. Detection was performed using
the ECL Plus Western Detection Reagents (Amersham).
FACS analysis
MCF-7 Cl27 cells were treated with 2 µM muristerone A
with or without the addition of 30 µM AdOX for 48 hours
prior to FACS analysis. For DAL-1/4.1B protein level
determinations, cells were collected following trypsiniza-
tion with 10 mM EDTA/1× PBS followed by two 1×
washes in PBS. All procedures were performed on ice.
Resuspended cells were then washed twice in 1× Staining
buffer (1× PBS containing 2% FCS, 1% human serum, 10
mM HEPES, and 0.025% sodium azide) and collected by
centrifugation at 200 g for 5 minutes at 4°C. Cells were
then fixed in 0.25% paraformaldehyde in 1× staining
buffer on ice for 30 minutes to 60 minutes. The buffer was
then replaced and cells permeablized in 0.2% Tween-20/
1XPBS at 37°C for 15 minutes after which 50 µl of human
serum was added to resuspend the cells. Primary antibody
(50  µl, rabbit polyclonal anti-DAL-1/4.1B antibody
diluted 1:50) was added and incubated on ice for 30 min-
utes. Cells were then washed twice in 0.2% Tween-20/
1XPBS buffer. Secondary antibody (phycoerythrin conju-
gate anti-rabbit IgG H+L (Vector) was added on ice in the
dark for 20 minutes followed by two washes in 0.2%
Tween-20/1XPBS buffer. Cells were then analyzed on the
FAC Calibur system (Becton Dickinson).
Apoptosis levels were assessed by Annexin-V (BD Bio-
science) and TUNEL (Roche) assays following manufac-
turer's recommendations. Briefly, cells were trypsinized in
Hypomethylation modulates apoptosis in MCF-7 Cl27 cells Figure 4
Hypomethylation modulates apoptosis in MCF-7 Cl27 cells. 
A. Western blot analysis with the anti-asymmetric dimethyl-
arginine antibody ASYM24 (Upstate Biochemical) shows sig-
nificant reduction in the methylation of proteins in MCF-7 
Cl27 cells when treated with 30 µM AdOX for 48 hours. B. 
TUNEL and global caspase activation assays show that 
AdOX-associated hypomethylation specifically increases the 
percentage of apoptotic cells in the presence of DAL-1/4.1B 
protein. Grey bars show the percentage of apoptotic cells as 
measured by TUNEL. Black bars represent the percentage of 
global caspase activation.Molecular Cancer 2006, 5:4 http://www.molecular-cancer.com/content/5/1/4
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10 mM EDTA/1XPBS and approximately 5 × 104 MCF-7
Cl27 cells were cultured in 500 µl medium in a 24 well
plate overnight prior to the addition of 2 µM muristerone
with or without 30 µM AdOX. Fresh medium was added
and cells were grown for 48 hours before measurement of
apoptosis levels. For cells treated with staurosporine
(STS), approximately 1 × 105 cells were treated with 1 µM
STS for 4 hours.
Caspase activation was analyzed using Carboxyfluores-
cein Caspase Detection Kits – FAM-VAD-FMK #FAM100
(Global Caspase), FAM-YVAD-FMK #FMK 600 (Caspase
1), FAM-VDVAD-FMK #FMK700 (Caspase 2), FAM-VEID-
FMK #FAM500 (Caspase 6), FAM-LETD-FMK #FAM300
(Caspase 8), and FAM-LEHD-FMK #FAM400 (Caspase 9)
from Cell Technology, and FAM-AEVD-FMK (Caspase 10)
and FAM-LEED-FMK (Caspase 13) from Immunochemis-
try Technology, LLC. APO LOGIX Carboxyfluoroscein
Caspase Detection Kits label active caspases in living cells
undergoing apoptosis. For caspase activation assays, cells
were plated as described above after which 20 ml of 30×
caspase solution was added. Plates were incubated at
37°C for 1.5 hours in the dark. The medium of each sam-
ple was then collected by centrifugation at 200 g for 10
minutes at 4°C. Remaining attached cells were washed
with 1× washing buffer and added to the non-adherent
cell pellets. Attached cells were then detached by treat-
ment with 0.01 M EDTA/1× PBS and all cell solutions
combined for analysis on the FAC Calibur system.
Caspase 8 inhibition and the effect on apoptosis levels
with and without expression of DAL-1/4.1B protein were
examined using the caspase 8-specific inhibitor z-IETD-
FMK (Calbiochem). MCF7 Cl27-inducible cells were
incubated with 0 mM, 15 µM, or 50 µM of inhibitor for
one hour prior to the induction of DAL-1/4.1B protein
expression and subsequent measurement of apoptosis by
Annexin V staining after 48 hours.
List of abbreviations
AdoHcy, S-adenosylhomocysteine; AdOX, adenosine
dialdehyde; DAL-1, differentially-expressed in adenocarci-
noma of the lung; FACS, fluorescence activated cell sort-
ing; FCS, Fetal calf serum; FERM, 4.1/ezrin/radixin/
moesin domain; NF2, neurofibromatosis 2; PBS, phos-
phate buffered saline; PRMT, protein arginine N-methyl-
transferase; SDS-PAGE, sodium dodecyl sulfate
polyacrylamide gel electrophoresis; STS, staurosporine.
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